

Table 3. The influence of variables on DFS and OS.

Covariate	CIR			DFS			OS		
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
EML (with vs. Without)	2.20	1.11-4.35	0.024	1.88	0.97-3.64	0.048	2.14	1.13-4.06	0.020
Consolidation (MDAC vs. SDAC)	0.20	0.10-0.39	0.000	0.22	0.12-0.42	0.000	0.18	0.09-0.36	0.000
C-KIT (mutated vs. WT)	1.80	0.92-3.50	0.088	1.80	0.95-3.40	0.095	1.80	0.96-3.35	0.065
WBC (≥ 20 vs. < 20)	1.25	0.67-2.33	0.484	1.09	0.60-1.97	0.774	0.87	0.45-1.70	0.683
Gender (male vs. female)	0.86	0.44-1.67	0.647	0.79	0.42-1.50	0.793	0.91	0.46-1.78	0.773
Age (≥ 14 vs. < 14)	1.09	0.54-2.20	0.821	0.94	0.49-1.81	0.848	1.29	0.61-2.74	0.508
CD34 (positive vs. negative)	1.34	0.42-4.31	0.626	1.31	0.48-3.62	0.602	1.11	0.40-3.09	0.841
CD33 (positive vs. negative)	1.65	0.74-3.70	0.222	1.55	0.76-3.17	0.226	1.57	0.70-4.49	0.272
CD13 (positive vs. negative)	0.59	0.29-1.22	0.156	0.69	0.35-1.35	0.277	0.62	0.30-1.28	0.194
CD117 (positive vs. negative)	0.71	0.30-1.66	0.425	0.75	0.34-1.65	0.474	0.72	0.31-1.70	0.457
HLA-DR (positive vs. negative)	1.16	0.46-2.92	0.755	0.77	0.38-1.56	0.464	0.71	0.33-1.51	0.709
CD19 (positive vs. negative)	0.90	0.49-1.65	0.727	0.78	0.44-1.36	0.376	0.63	0.33-1.20	0.159
CD56 (positive vs. negative)	1.22	0.69-2.15	0.495	1.04	0.63-1.73	0.865	1.26	0.72-2.21	0.427
ACAs (with vs. without)	0.66	0.30-1.44	0.298	0.74	0.36-1.51	0.409	0.83	0.37-1.89	0.643
FLT3-ITD (mutated vs. WT)	2.38	0.80-7.14	0.121	1.96	0.67-5.78	0.221	2.16	0.62-7.47	0.226
NPM1 (mutated vs. WT)	2.37	0.32-17.72	0.401	1.89	0.26-12.92	0.582	1.89	0.26-14.00	0.533

CIR, cumulative incidence of relapse; DFS, disease-free survival; OS, overall survival; EML, extramedullary leukemia; SDAC, standard dose cytarabine; MDAC, median dose cytarabine; WT, wild type; WBC, white blood cell; ACAs, additional chromosomal abnormalities.